By Josh Beckerman
Abbott Laboratories (ABT) led $45 million of financing for Bigfoot Biomedical, the initial tranche of a Series C round.
The funding also included Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management.
Bigfoot is developing the Bigfoot Unity Diabetes Management Program, an insulin dosing platform that integrates Abbott's FreeStyle Libre glucose sensing technology.
Write to Josh Beckerman at firstname.lastname@example.org